The independent source for health policy research, polling, and news.
PEPFAR Reauthorization on the Horizon
In this Think Global opinion piece, Jennifer Kates and Kellie Moss discuss what could happen if the United States’ signature initiative on global health is not reauthorized.
Read PostIncreasingly Privatized Public Health Insurance Programs in the US
In this JAMA Forum column, KFF’s Larry Levitt examines the growing role of private insurance companies in public programs, including Medicare Advantage and Medicaid managed care, and the tradeoffs that result.
Read PostThe Commercialization of Covid Vaccines Is Coming. Here’s What It Means.
In this commentary for Barron’s, KFF’s Cynthia Cox and Jennifer Kates explore what will happen with costs to COVID-19 vaccines for people with and without insurance once the relevant public health emergency ends on May 11.
Read PostMedicaid as a Potential New Third Rail of US Politics
In this JAMA Forum column, KFF’s Larry Levitt examines Medicaid’s growing political importance and the potential double whammy that could hit state Medicaid programs next year with the end of the COVID-19 public health emergency and a possible simultaneous recession.
Guest Essay Read PostThe Inflation Reduction Act is a Foot in the Door for Containing Health Care Costs
In this column for the JAMA Forum, KFF’s Larry Levitt explores the Medicare drug-price negotiation provisions and other significant drug-price changes in the Inflation Reduction Act and their potential to lead to further efforts to address health care costs.
Guest Essay Read PostThe Biggest Health Care Reform in a Decade Could Lower Your Costs
Larry Levitt writes about the political and practical impact of the health care provisions in the Inflation Reduction Act in The New York Times guest essay, “The Biggest Health Care Reform in a Decade Could Lower Your Costs.”
Guest Essay Read Post